Patient characteristics before and after IPTW.
| Before IPTW | After IPTW | |||||
| 2011–2013 (N=3470) | 2015–2017 (N=5772) | Std. Diff. (%) | 2011–2013 (N=3470) | 2015–2017 (N=5772) | Std. Diff. (%) | |
| Age, mean | 61 | 64.2 | 31.60 | 62.83 | 62.9 | 0.90 |
| Gender | ||||||
| Female | 28.60% | 33.90% | 11.30 | 31.60% | 31.80% | 0.50 |
| Male | 71.40% | 66.10% | 11.30 | 68.40% | 68.20% | 0.50 |
| Race | ||||||
| White | 82.20% | 82.30% | 4.00 | 82.40% | 82.30% | 0.20 |
| Black | 8.80% | 7.70% | 4.30 | 8.10% | 8.10% | 0.00 |
| Hispanic | 4.30% | 5.10% | 3.70 | 4.80% | 4.80% | 0.40 |
| Asian | 1.70% | 1.60% | 1.00 | 1.60% | 1.60% | 0.10 |
| Unknown | 3.00% | 3.30% | 2.10 | 3.20% | 3.20% | 0.10 |
| Baseline characteristics | ||||||
| Amiodarone use | 9.00% | 12.00% | 12.60 | 11.00% | 11.00% | 0.80 |
| Anemia | 21.00% | 19.00% | 4.40 | 20.00% | 20.00% | 0.20 |
| Vascular disease | 24.00% | 27.00% | 5.90 | 26.00% | 26.00% | 0.20 |
| COPD | 6.00% | 5.00% | 3.00 | 6.00% | 6.00% | 0.10 |
| Obesity | 31.00% | 43.00% | 23.80 | 38.00% | 38.00% | 0.30 |
| Hypertension | 78.00% | 81.00% | 7.40 | 80.00% | 80.00% | 0.30 |
| Diabetes | 19.00% | 23.00% | 10.40 | 22.00% | 21.00% | 0.90 |
| Renal disease | 7.00% | 12.00% | 16.20 | 10.00% | 10.00% | 0.80 |
| CHF | 24.00% | 28.00% | 8.60 | 27.00% | 27.00% | 0.90 |
| Cardioversion | 41.00% | 43.00% | 3.90 | 42.00% | 42.00% | 0.20 |
| Stroke | 7.00% | 3.00% | 18.90 | 5.00% | 5.00% | 0.30 |
| HAS-BLED, mean* | 1.7 | 1.9 | 14.40 | 1.8 | 1.9 | 2.70 |
| CHA2DS2-VASc, mean* | 2.4 | 2.7 | 23.10 | 2.6 | 2.6 | 4.70 |
*Not included in IPTW.
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; IPTW, inverse probability of treatment weighting.